<PAGE> 1
EXHIBIT 10.11
AMENDMENT TO CROSS-LICENSING AGREEMENT
This is an Amendment to the Cross-Licensing Agreement between Masimo
Laboratories and Masimo Corporation, dated May 2, 1998 (The Original Agreement).
WHEREAS, Masimo Laboratories and Masimo Corporation desire to extend the
option period in the Original Agreement by one year.
NOW, THEREFORE, For good and valuable consideration, the receipt and
sufficiency of which are acknowledged by the Parties, the original Agreement is
amended as follows:
SECTION 4.2 IS AMENDED AS FOLLOWS: Option Fee. MASIMO agrees to fund the
research and development conducted by LABS related to, among other things,
noninvasive blood glucose measurement, for a period of up to four (4) years
following the effective date of this Agreement, and in an amount of two million
five hundred thousand dollars ($2,500,000). LABS will request reimbursement for
such research costs no more often than monthly, and MASIMO shall reimburse LABS
for such research within 30 days following receipt of such request for
reimbursement. MASIMO understands that LABS has no proof of concept for glucose
and total hemoglobin measurements.
MASIMO CORPORATION MASIMO LABORATORIES,
By /s/ JOE E. KIANI By /s/ BRAD LANGDALE
--------------------- ----------------------
Joe E. Kiani Brad Langdale
President and CEO Executive Vice President and Secretary
Dated: 3-20-00 Dated: 3/20/00
----------------- ----------------
